argenx (ENXTBR:ARGX) Gets Mixed Trial News, Is It Still Overvalued?
Argenx (ARGX) reported positive Phase 2 data for FB102 in celiac disease and halted its Phase 3 UNITY trial in Sjögren's disease. The stock has fallen 18.5% over 30 days, but long-term returns remain strong. Analysts debate its valuation, with some seeing it as slightly overvalued at €705.60, while a DCF model suggests significant undervaluation at €2,651.18.
How this was made
The 30-second read
Why it matters
The mixed trial news creates immediate volatility, with the trial halt likely driving short‑term price declines, while the Phase 2 success may support longer‑term valuation arguments.
Market read
Direct impact on ARGX stock; indirect pressure on European biotech sector.
What to watch
Potential for a strategic partnership or licensing deal for FB102 that could offset the UNITY setback.
Background
The article is a Simply Wall St commentary summarizing recent trial updates for argenx and providing valuation perspectives.
Market effects
May dampen sentiment in the broader biotech sector as trial failures raise risk perception.
European biotech indices could see modest declines.
Limited to biotech investors; no broad market effect.
Counterpoint
The positive FB102 Phase 2 data could be a catalyst for a rebound if the company secures further funding or partnership.
Key entities
- companyargenx
Biotech firm developing VYVGART and pipeline candidates FB102 and UNITY.
